No. The data Eisai provided to the FDA suggests there’s no elevated risk of side effects for Leqembi Iqlik. The rates of brain swelling and microhemorrhages known as Amyloid-Related Imaging Abnormalities (ARIA) are equivalent across the two formulations of the drug.